Evidence map›Paper›PMID 34560047›Full record

ArticleAmerican journal of obstetrics and gynecology2022

Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.

Andrew T Gustin, Andrea R Thurman, Neelima Chandra, Luca Schifanella, Maria Alcaide, Raina Fichorova, Gustavo F Doncel, Michael Gale, Nichole R Klatt

Open access · greenAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Contribution ofFrontiers in cellular and infection microbiology · 2021
    Pooled it
  3. Trial
  4. Orally administratedFrontiers in immunology · 2023
    Trial
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  15. Article
  16. Molecular Exploration ofPathogens (Basel, Switzerland) · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Andrew T GustinDepartment of Global Health, University of Washington, Seattle, WA; Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA.
Andrea R ThurmanCONRAD, Eastern Virginia Medical School, Norfolk, VA.
Neelima ChandraCONRAD, Eastern Virginia Medical School, Norfolk, VA.
Luca SchifanellaDivision of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN.
Maria AlcaideDepartment of Medicine.
Raina FichorovaDepartment of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA.
Gustavo F DoncelCONRAD, Eastern Virginia Medical School, Norfolk, VA.
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA.
Nichole R KlattDivision of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN; Department of Pediatrics, University of Miami, Miami, FL. Electronic address: klat0037@umn.edu.
Eastern Virginia Medical School · USUniversity of Washington · USHarvard University · USUniversity of Miami · USUniversity of Minnesota Medical Center · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Innate Immune Regulation of Zika Virus InfectionR01AI145296 · NIAID · UNIVERSITY OF WASHINGTON · PI COYNE, CAROLYN B, DIAMOND, MICHAEL S · 2019 to 2023
$4.1M
Mechanisms underlying recurrent bacterial vaginosis and HIV risk A Multidisciplinary approachR01AI138718 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALCAIDE, MARIA LUISA · 2018 to 2023
$3.5M
Mechanisms of hepatic innate immune activation by HCVR01AI127463 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL, ROSEN, HUGO RAMON · 2017 to 2021
$2.8M
Targeting novel pathways to enhance gastrointestinal integrity during HIV infectionR01DK112254 · NIDDK · UNIVERSITY OF WASHINGTON · PI BURGENER, ADAM, KLATT, NICHOLE ROSE · 2017 to 2021
$1.8M
NIAID NIH HHS R01 AI127463NIAID NIH HHS R01 AI138718NIAID NIH HHS R01 AI145296NIAID NIH HHS U01 AI151698NIDDK NIH HHS R01 DK112254NIH HHS P51 OD010425
6 · The paper itself

Abstract

backgroundBacterial vaginosis-a condition defined by a shift from Lactobacillus dominance to a polymicrobial, anaerobic bacterial community-increases the risk of acquiring sexually transmitted infections and other complications of the female reproductive tract. Antibiotic treatment frequently fails to return the microbiome to an optimal Lactobacillus-dominated state. No criteria currently exist to identify the patients likely to experience treatment failure.

objectiveWe sought to identify the pretreatment community signatures associated with treatment failure through 16S ribosomal RNA gene analysis. STUDY

designTwenty-eight women who were enrolled in an oral metronidazole treatment trial of bacterial vaginosis were studied. Cervicovaginal lavage samples were collected before metronidazole treatment and at 7 and 30 days posttreatment. Cervicovaginal lavage DNA was amplified and sequenced using a paired-end, V4 region 2×150 MiSeq run.

resultsOf the 28 women, 25% failed to clear bacterial vaginosis; 35.7% demonstrated a transient clearance, shifting to community-type 2 (Lactobacillus iners dominant) at visit 2 only; 7.1% demonstrated a delayed clearance, reaching community-type 2 at the final visit only; and 32.1% of patients experienced sustained bacterial vaginosis clearance. Examination of the community composition and structure demonstrated that both the richness and the evenness were significantly lower for the women who experienced sustained clearance, whereas the women who failed to clear bacterial vaginosis possessed the highest median levels of richness, evenness, and diversity pretreatment. Soluble immune factors in the lower reproductive tract improved significantly following a shift from community-type 4 to a Lactobacillus-dominant microbiome, with the samples categorized as community-type 2 possessing significantly higher levels of secretory leukocyte protease inhibitor, growth-regulated alpha protein, and macrophage inflammatory protein-3 and significantly lower levels of intercellular adhesion molecule-1. Although the shifts to Lactobacillus dominance improved the markers of mucosal tissue health, these gains were only temporary among the women who experienced recurrence.

conclusionAssemblies of highly diverse microbiota are associated with the enhanced resilience of bacterial vaginosis to standard metronidazole treatment. These communities may be foundational to treatment resistance or simply an indication of a well-established community made possible by canonical biofilm-forming taxa. Future studies must target the transcriptional activity of these communities under the pressure of antibiotic treatment to resolve the mechanisms of their resistance.

Indexed as

AdultAnti-Bacterial AgentsFemaleHumansLactobacillusLongitudinal StudiesMetronidazoleMicrobiotaRecurrenceTreatment FailureVaginaVaginosis, BacterialAnti-Bacterial AgentsMetronidazoleantibioticsbacterial vaginosis recurrencebiofilmsmolecular bacterial vaginosismucosal immunityvaginal microbiome

Identifiers

PMID34560047
PMCPMC8887553
OpenAlexW3201029957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.